These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 3045435)

  • 1. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
    Ahlskog JE; Muenter MD; McManis PG; Bell GN; Bailey PA
    Mayo Clin Proc; 1988 Sep; 63(9):876-86. PubMed ID: 3045435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
    Hutton JT; Morris JL; Román GC; Imke SC; Elias JW
    Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
    Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
    Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
    Sage JI; Mark MH
    Clin Neuropharmacol; 1988 Apr; 11(2):174-9. PubMed ID: 3378226
    [No Abstract]   [Full Text] [Related]  

  • 7. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
    Bush DF; Liss CL; Morton A
    Neurology; 1989 Nov; 39(11 Suppl 2):101-4; discussion 105. PubMed ID: 2685646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR).
    Cedarbaum JM; Silvestri M; Clark M; Toy L; Harts A; Green-Parsons A; McDowell FH
    J Neural Transm Park Dis Dement Sect; 1990; 2(3):205-13. PubMed ID: 2257060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
    Cedarbaum JM; Hoey M; McDowell FH
    J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):207-12. PubMed ID: 2649640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group.
    Wolters EC; Horstink MW; Roos RA; Jansen EN
    Clin Neurol Neurosurg; 1992; 94(3):205-11. PubMed ID: 1327609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
    Rondot P; Ziegler M; Aymard N; Teinturier A
    Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
    Goetz CG; Tanner CM; Shannon KM; Carroll VS; Klawans HL; Carvey PM; Gilley D
    Neurology; 1988 Jul; 38(7):1143-6. PubMed ID: 3290706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
    Jankovic J; Schwartz K; Vander Linden C
    Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease.
    Wolters EC; Tesselaar HJ
    J Neurol; 1996 Mar; 243(3):235-40. PubMed ID: 8936353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
    Goetz CG; Tanner CM; Gilley DW; Klawans HL
    Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.